| scholarly article | Q13442814 |
| P50 | author | Sandirai Musuka | Q117260819 |
| Tawanda Gumbo | Q40336008 | ||
| Shashikant Srivastava | Q56381433 | ||
| Devyani Deshpande | Q58917103 | ||
| P2860 | cites work | Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria | Q22241907 |
| Incorporation of (3H)palmitate and (14C)choline into disaturated phosphatidylcholines in rat alveolar macrophages | Q26343042 | ||
| Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis | Q28486661 | ||
| The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions | Q33178661 | ||
| Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. | Q33798280 | ||
| Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients | Q34045450 | ||
| Evolution in changing environments: modifiers of mutation, recombination, and migration | Q34752908 | ||
| A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example | Q35097554 | ||
| An evolutionary reduction principle for genetic modifiers | Q35614856 | ||
| The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance | Q36172383 | ||
| Distribution of mycobacterial antigen based on differences of histological characteristics in pulmonary Mycobacterium avium infectious diseases--consideration of the extent of surgical resection from the pathological standpoint | Q83003982 | ||
| Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps | Q36705837 | ||
| An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases | Q36727850 | ||
| Interpretation of antibiotic concentration ratios measured in epithelial lining fluid | Q36936597 | ||
| Significance of Serum Protein and Tissue Binding of Antimicrobial Agents | Q37034927 | ||
| Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners | Q37335803 | ||
| Synthesis and assembly of lung surfactant | Q37739434 | ||
| The broad-spectrum antimycobacterial activities of phenothiazines, InVitro: somewhere in all of this there may be patentable potentials | Q37868591 | ||
| Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium | Q37869912 | ||
| Protein binding: do we ever learn? | Q37871252 | ||
| Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents | Q37927017 | ||
| Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia | Q38502298 | ||
| Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes | Q38979626 | ||
| The role of efflux pumps in macrolide resistance in Mycobacterium avium complex | Q39404012 | ||
| Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis | Q39404019 | ||
| The potential role of lysosomes in tissue distribution of weak bases | Q39563115 | ||
| The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient. | Q39563382 | ||
| Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection | Q39715580 | ||
| Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium | Q40335980 | ||
| Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia | Q40609169 | ||
| Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm | Q40679730 | ||
| Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments | Q41082086 | ||
| Interactions of chlorpromazine and imipramine with artificial membranes investigated by equilibrium dialysis, dual-wavelength photometry, and fluorimetry | Q41668368 | ||
| Role of Lysosomes in Hepatic Accumulation of Chloroquine | Q41912287 | ||
| Thioridazine cardiotoxicity | Q42556427 | ||
| Evolutionarily stable mutation rate in a periodically changing environment. | Q42960953 | ||
| Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. | Q44374404 | ||
| Changes in lipid structure produced by surfactant proteins SP-A, SP-B, and SP-C. | Q45156342 | ||
| Binding of basic and acidic drugs to rat tissue subcellular fractions | Q47877466 | ||
| Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. | Q48156900 | ||
| Membrane lipids as intracellular binders of chlorpromazine and related drugs | Q48308513 | ||
| Role of mutator alleles in adaptive evolution. | Q54564129 | ||
| Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease | Q58321694 | ||
| Plasma levels and half lives of thioridazine and some of its metabolites. II. Low doses in older psychiatric patients | Q67549282 | ||
| Modifiers of mutation rate: a general reduction principle | Q69602852 | ||
| Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart | Q69630201 | ||
| Tissue distribution of chlorpromazine studied by microautoradiography | Q71478019 | ||
| Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection | Q77967992 | ||
| Clinical, biochemical and post mortem studies on a patient treated with chlorpromazine | Q79542790 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium avium avium | Q310728 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 4652-4658 | |
| P577 | publication date | 2016-05-23 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases | |
| P478 | volume | 60 |
| Q41996877 | A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease |
| Q41996885 | A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease |
| Q41996871 | A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting |
| Q88909426 | Clofazimine for the Treatment of Mycobacterium kansasii |
| Q90781984 | Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithromycin |
| Q41996903 | Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance |
| Q41996896 | Linezolid as treatment for pulmonary Mycobacterium avium disease |
| Q92704112 | Looking beyond Typical Treatments for Atypical Mycobacteria |
| Q55340853 | Mycobacterial Response to Organic Solvents and Possible Implications on Cross-Resistance With Antimicrobial Agents. |
| Q41996895 | Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease |
| Q41996889 | The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent |
| Q42650868 | Treatment with high-dose antidepressants severely exacerbates the pathological outcome of experimental Escherichia coli infections in poultry. |
Search more.